Exicure, Inc.
4.4600-0.09 (-1.98%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · XCUR · USD
Key Stats
Market Cap
28.18MP/E (TTM)
-Basic EPS (TTM)
-3.86Dividend Yield
0%Recent Filings
8-K
Board adds two, loses four
Exicure's board reshaped on September 8, 2025, with Sangjn Yeo and Aejin Hwang appointed as Class II directors, filling two seats while four others—Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang—resigned without disagreements. Yeo chairs the audit committee, joined by Hwang; each earns a $20,000 annual retainer. Four vacancies remain. This shift bolsters governance oversight amid biotech transitions.
8-K
Exicure's Q2 loss widens
Exicure reported a $2.6 million net loss for Q2 2025, up from $0.6 million last year, driven by $0.9 million in new R&D expenses after acquiring GPCR USA, which boosted G&A by $0.3 million too. Cash dwindled to $7.9 million from $12.5 million at year-end, signaling tight finances. Substantial funding is urgently needed. Operations burn fast now.
10-Q
Q2 FY2025 results
Exicure posted a Q2 net loss of $2.6M, up from $0.6M last year, as research and development costs hit $0.9M following the January 2025 acquisition of GPCR USA for $7.9M total consideration (cash/equity mix), recognizing $3.3M goodwill and $3.8M intangible assets. Yet YTD through June 30, 2025, the company swung to a $0.4M profit from a $1.4M loss, fueled by a $6.0M gain on early Chicago lease termination that offset rising expenses. Cash dipped to $7.9M from $12.5M at year-end, with operating cash burn at $3.9M and free cash flow negative $4.2M (derived); no debt lingers after 2024 conversions. GPCR USA wrapped dosing for 20 patients in its Phase 2 multiple myeloma trial, eyeing Q4 data. Litigation shadows persist from ongoing derivative suits.
8-K
Exicure regains Nasdaq compliance
Exicure regained Nasdaq compliance on July 1, 2025, after filing its Q1 10-Q for the quarter ended March 31, 2025, resolving prior deficiencies under Listing Rule 5250(c)(1). The company, post-restructuring and clinical suspension, now explores strategic alternatives to boost stockholder value. Compliance restored. This clears a key hurdle amid asset maximization efforts.
8-K
Exicure Q1 profit amid cash crunch
Exicure swung to a $3.0 million net income for Q1 2025, fueled by a $6 million gain from early Chicago lease termination, yet cash dipped to $10.4 million from $12.5 million. The acquisition of GPCR USA sparked $0.8 million in R&D and $0.9 million higher G&A expenses. Cash won't sustain operations long; financing hunt intensifies. Strategic alternatives loom large.
CPMV
Mosaic ImmunoEngineering Inc.
0.84+0.33
CURX
Curanex Pharmaceuticals Inc
0.71-0.05
EPIX
ESSA Pharma Inc.
0.20+0.00
EXOZ
eXoZymes Inc.
12.65+0.29
NBY
NovaBay Pharmaceuticals, Inc.
1.20-0.06
OKUR
OnKure Therapeutics, Inc.
3.19-0.14
PTIX
Protagenic Therapeutics, Inc.
2.58-0.18
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XBIT
XBiotech Inc.
2.37+0.00
YDES
YD Bio Limited
13.24-2.56